logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
ABIVAX SA
(ABVX.PA)
ABX464 for COVID-19
Phase 2b/3 study of ABX464 in COVID-19 patients (miR-AGE)
Results from the miR-AGE study expected by year-end
-
07/02/2020
DURECT Corp.
(DRRX)
DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
Phase 2 study of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury
-
-
07/01/2020
Proteostasis Therapeutics, Inc.
(PTI)
PTI-129 as a treatment for COVID-19
Peclinical
-
-
06/30/2020
PTC Therapeutics Inc.
(PTCT)
PTC299 for the treatment for COVID-19
FDA has authorized initiation of a Phase 2/3 trial of PTC299
-
-
06/30/2020
HUMANIGEN, INC
(HGEN)
Lenzilumab in Severe and Critical COVID-19 Patients
Phase III trial of Lenzilumab in severe and critical COVID-19 patients
-
-
06/30/2020
Citius Pharmaceuticals, Inc.
(CTXR)
iMSC therapy to treat ARDS in COVID-19 patients
Research
Submit an IND application for iMSC therapy for patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19
-
06/30/2020
Previous Records

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Biotech Stocks Facing FDA Decision In July 2020 Virtual Meetings Pandemic Rare Diseases colonoscopy and bronchoscopy

Biotech Stocks Facing FDA Decision In July 2020
New Drugs Approved In May

New Drugs Approved In May
Biotech Stocks Facing FDA Decision In June 2020 COVID19 papulopustular rosacea pneumonia NASH NMOSD Keytruda follicular lymphoma

Biotech Stocks Facing FDA Decision In June 2020
Editors Pick
Polaris Recalls Ranger And General Utility, All-Terrain Vehicles
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.
EU Gives Conditional Market Authorization For Gilead's Remdesivir Treat COVID-19
Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
FedEx Asks Washington Redskins Team To Change Name
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Latest Updates on COVID-19
Slideshow iconCountries that tamed coronavirus
Read More
COVID-19: Drugs in Development
Copyright © 2020 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap